Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 07/02/2017

    Atriva receives seed financing to develop its next generation influenza therapeutic

    The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinical development stage.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-receives-seed-financing-to-develop-its-next-generation-influenza-therapeutic
  • Press release - 30/11/2016

    Takeda to invest more than 100 Million Euros in Dengue Vaccine Manufacturing plant in Germany

    Konstanz, Germany, November 29, 2016 and Osaka, Japan, November 30, 2016 – Takeda Pharmaceuticals Company Limited, (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/takeda-to-invest-more-than-100-million-euros-in-dengue-vaccine-manufacturing-plant-in-germany
  • Press release - 04/11/2016

    Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-therapeutics-announces-upcoming-us-patent-issuance-for-mek-treatment-against-viral-diseases
  • Article - 20/09/2016 Prof. Dr. Anita Marchfelder, spokesperson and coordinator of the DFG research group FOR1680.

    CRISPR-Cas has more surprises in store

    Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store
  • Article - 22/08/2016 Schematic of a modified virus.

    Ad-O-Lytics – a new biotech start-up from Ulm

    A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
  • Article - 18/08/2016 HCV_particles_EM.jpg

    Chronic viral infections of the liver

    Hepatitis B and hepatitis C are two of the most common infectious diseases in the world. They often take a chronic course and carry a high risk of progressing to cirrhosis and hepatocellular carcinoma. A new transregional collaborative research centre involving scientists from Heidelberg and Freiburg is looking into how hepatitis B and hepatitis C viruses, which have different symptoms and treatments, are able to evade the immune system and allow…

    https://www.gesundheitsindustrie-bw.de/en/article/news/chronic-viral-infections-of-the-liver
  • Article - 08/08/2016 Schematic cut through an eye into which the gene therapy is injected.

    First achromatopsia gene therapy clinical trial in Germany is going well

    Around 3000 people suffer from achromatopsia in Germany. Achromatopsia is an inherited visual disorder characterised by the absence of full colour vision. The disease is caused by a genetic defect that makes the retina's cone photoreceptors, needed for daylight and colour vision, non-functional. There is currently no cure for achromatopsia. Scientists from Tübingen University Hospital and their colleagues from Munich and New York have now…

    https://www.gesundheitsindustrie-bw.de/en/article/news/first-achromatopsia-gene-therapy-clinical-trial-in-germany-is-going-well
  • Article - 27/07/2016 The left part of the schematic shows the phylogenetic tree of Ebola viruses. The different regions where the Ebola viruses were found are represented in different colours. The right side shows a map of West Africa; the regions where the viruses used for the analysis were found have the same colour as the respective lines in the tree.

    “Open science“ – a successful recipe for combating viruses

    Danger identified, danger averted – the better the dynamic changes of the viral genome are understood, the better the spread of the pathogens can be predicted, thus enabling more efficient countermeasures to be taken. A team of researchers from Tübingen and Seattle is developing an open source online platform that maps the evolution of viruses and identifies dangerous developments.

    https://www.gesundheitsindustrie-bw.de/en/article/news/open-science-a-successful-recipe-for-combating-viruses
  • Company profile - 27/06/2016 Schematic showing a host cell that is infected by an influenza virus that uses the MEK signalling pathway in the host cells to propagate (left). Several new viruses (red) have been released by the host cell. The schematic on the right-hand side shows the blockage of the signalling pathway. Crossed-out grey virus cells below the host cell indicate that the viruses are no longer able to replicate.

    Atriva Therapeutics GmbH: new ways to treat influenza

    Influenza viruses constantly change and mutate. This makes treatment difficult and vaccination rather touch and go. But what about targeting virus-manipulated cell events rather than using the virus itself as drug target? Atriva Therapeutics GmbH, a start-up company from Tübingen, shows how this works.

    https://www.gesundheitsindustrie-bw.de/en/article/news/atriva-therapeutics-gmbh-new-ways-to-treat-influenza
  • Article - 02/05/2016 Schematic showing immune cells recognise a hepatitis C virus.

    Hepatitis C: a new starting point for vaccine development

    With approximately 150,000 infected people in Germany, hepatitis C is a common disease for which therapies, but no vaccine, are available. Dr. Tobias Böttler from the Freiburg University Medical Center and his team are exploring the body’s immune response to the hepatitis C virus (HCV) and have found valuable information that could be used for vaccine development.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hepatitis-c-a-new-starting-point-for-vaccine-development
  • Article - 11/04/2016 Schematic representation of a big, blue, spherical virus.

    Glycovirology: carbohydrate molecules against infections

    Many viruses enter cells by way of carbohydrate molecules known as glycans to which they bind during the initial steps of infection. However, it is still largely unknown how glycan-mediated infection proceeds. This is about to change with a working group that has been set up by the DFG at the University of Tübingen and five other universities. The group will focus on glycovirology, a new scientific area that aims to understand the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/glycovirology-carbohydrate-molecules-against-infections
  • Article - 15/02/2016 Rolf Backofen sitting in front of his PC.

    Bacteria – a treasure box for genetic engineers

    Bacteria have developed a versatile defence system to protect themselves against viral infections. One of these defence tools, known as CRISPR/Cas9 system, is currently hogging the headlines as it promises to revolutionise the way genetic material can be modified. Prof. Rolf Backofen from the Institute of Bioinformatics at the University of Freiburg has managed to classify the defence system of all bacterial species sequenced to date. This will…

    https://www.gesundheitsindustrie-bw.de/en/article/news/bacteria-a-treasure-box-for-genetic-engineers
  • Press release - 12/02/2016

    ERC Consolidator Grants: € 585 million for 302 top researchers in Europe

    The European Research Council (ERC) has announced today the 302 winners of its 2015 Consolidator Grant competition. These excellent mid-career scientists are awarded a total of €585 million, as part of the European Union Research and Innovation programme Horizon 2020. With grants worth up to €2 million each, they will be able to consolidate their research teams and to develop their innovative ideas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-consolidator-grants-585-million-for-302-top-researchers-in-europe
  • Article - 24/11/2015 The researchers from Tübingen were able to decipher in detail the site where the JC polyomavirus binds to the host cell. The yellow molecule structure shows the sugar residues on the surface of the host cell encased in the binding pocket of the viral protein.

    Researchers from Tübingen set out to thwart viral survival strategies

    Around two thirds of people carry the JC polyomavirus, a normally harmless virus that, in immunocompromised patients, can evade the body’s defences and cause a fatal brain infection. An international research network has now found a way to activate the immune system and attack the virus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/researchers-from-tuebingen-set-out-to-thwart-viral-survival-strategies
  • Vaccine development - 02/11/2015 Valerie_Herrmann.jpg

    A new vaccine could prevent influenza epidemics

    Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target groups for quite a few years now. However, producing vaccines is costly and time-consuming. Researchers at the University…

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-new-vaccine-could-prevent-influenza-epidemics
  • Article - 24/09/2015 ESEQuant_LR3.jpg

    New test system for detection of HPV-related oral cavity cancers

    The number of people suffering from oral or oropharyngeal cancer is rising steadily. The major cause of these cancers is human papillomaviruses (HPV) that colonise the oral cavity, where they are difficult to detect. QIAGEN Lake Constance GmbH from Stockach, in cooperation with Abviris Deutschland GmbH, has developed a new test system to improve the detection of oral HPV. This new system enables rapid and reliable quantitative detection of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-test-system-for-detection-of-hpv-related-oral-cavity-cancers
  • Pharmaceutical research and life sciences profit from unique biosensor technology - 18/09/2015 biametrics_Logo.jpg

    Biametrics GmbH concludes financing round with 3.1 Million Euro

    Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioanalytical business activities to an international level. The fresh capital will facilitate the…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biametrics-gmbh-concludes-financing-round-with-31-million-euro
  • Article - 20/07/2015 23437_de.jpg

    Liver cell carcinoma: reducing tumour burden – increasing life expectancy

    Liver cell carcinoma or hepatocellular carcinoma (HCC) is one of the most malignant human cancers. The disease arises from chronic damage to the liver, usually caused by virus- or alcohol-related liver cirrhoses. Liver tumours are considered difficult to treat, but there is evidence that they actually trigger an immune response in the body. Prof. Dr. Robert Thimme from Freiburg University Medical Centre is seeking to understand this effect and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/liver-cell-carcinoma-reducing-tumour-burden-increasing-life-expectancy
  • Article - 06/07/2015 23430_de.jpg

    Blood stem cells deliver drugs to brain tumours

    The brain is the central switchboard in our body. Professor Ghazaleh Tabatabai’s work focuses specifically on the brain and the fight against uncontrolled proliferation of brain tumours. In May 2014, she was appointed professor in the newly established Interdisciplinary Division of Neuro-Oncology at the University of Tübingen and head of the Clinical and Experimental Neuro-Oncology research group at the Hertie Institute for Clinical Brain…

    https://www.gesundheitsindustrie-bw.de/en/article/news/blood-stem-cells-deliver-drugs-to-brain-tumours
  • Article - 29/06/2015 Neher sitting in front of his computer, pointing at a drawing on the screen.

    How can influenza virus prediction be improved?

    Every February, the World Health Organisation (WHO) publishes recommendations on the composition of influenza virus vaccines for use in the upcoming influenza season. The WHO’s decision is based on observations and laboratory tests as well as experience and intuition. The particular type of influenza virus that is likely to be circulating in a given season has previously been mainly a matter of speculation. Richard Neher from the Max Planck…

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-can-influenza-virus-prediction-be-improved
  • Article - 26/05/2015 23292_de.jpg

    Does too much beef and cow’s milk cause cancer?

    The large number of breast and colon cancer cases might be due to viruses that are taken up with beef and dairy products. This is the provocative thesis of Nobel Laureate Harald zur Hausen who previously linked HPV with cervical cancer. In addition to epidemiological evidence, zur Hausen and his team have also provided experimental evidence to substantiate his thesis.

    https://www.gesundheitsindustrie-bw.de/en/article/news/does-too-much-beef-and-cows-milk-cause-cancer
  • Article - 26/05/2015 Photo showing Prof. Dr. Christiane Wobus.

    Christiane Wobus does norovirus research in two completely different environments

    Prof. Dr. Christiane Wobus researches mouse-specific noroviruses. The virologist is seeking to clarify the interaction between viral particles upon contact with host cells. The scientist normally lives in the USA, but has returned to Germany for a 12-month period thanks to a Humboldt Fellowship. She will be working at the Interfaculty Institute of Biochemistry at Tübingen in Germany where, amongst other things, she highly rates the cooperation…

    https://www.gesundheitsindustrie-bw.de/en/article/news/christiane-wobus-does-norovirus-research-in-two-completely-different-environments
  • Article - 18/05/2015 The figures shows a model of a spherical parvovirus. Parvoviruses are non-enveloped viruses, which makes them rather resistant against external influences.

    Parvoviruses can destroy brain tumours

    Parvoviruses such as H-1PV have been shown to selectively attack and destroy human cancer cells. However, they are unable to replicate in healthy human cells. A preliminary clinical trial is currently being carried out to assess the suitability of parvoviruses for treating malignant brain cancer. Scientists from the German Cancer Research Center (DKFZ) have now discovered the cause of the selective effect of H-1PV. The finding helps identify…

    https://www.gesundheitsindustrie-bw.de/en/article/news/parvoviruses-can-destroy-brain-tumours
  • Article - 22/04/2015 23162_de.jpg

    AIDS viruses play hide and seek

    AIDS-causing HI viruses preferentially integrate into transcriptionally active genes of the host cell genome. These gene regions are located in the immediate vicinity of the nuclear pores. A team of researchers from Heidelberg University Hospital and colleagues from Italy have now shown that the integration of the viruses is controlled by components of the nuclear pores. These findings are an important step towards gaining a detailed…

    https://www.gesundheitsindustrie-bw.de/en/article/news/aids-viruses-play-hide-and-seek
  • Article - 09/03/2015 22905_de.jpg

    Treating cancer by activating the immune system

    Vaccines that prevent infection with cancer-causing viruses are already available. Moreover, the development of therapeutic vaccines for the treatment of a number of other cancers is well under way. These vaccines not only prevent the development of cancer, but also treat early stages of cancer. Antigen-armed antibodies have long been used in vaccines against infectious diseases, and can now also be used for treating cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/treating-cancer-by-activating-the-immune-system

Page 4 / 8

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search